On June 3, 2019 BioInvent International AB (OMXS: BINV) reported the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application for a Phase I/IIa clinical trial of an immune-modulatory anti-FcγRllB antibody in combination with an anti-PD1 antibody in solid tumors (Press release, BioInvent, JUN 3, 2019, View Source [SID1234536820]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The anti-FcγRllB antibody is part of BioInvent’s FcγRIIB-targeting program, which has emerged from its F.I.R.S.T platform technology. It simultaneously identifies both targets and high-quality antibodies that bind to them, generating potentially promising new drug candidates.

"There is a strong rationale to improve the therapeutic efficacy of anti-PD1 antibodies, and this study with our first-in-class monoclonal antibody offers the opportunity to improve treatment of solid cancers. It is a further example of how BioInvent’s platform is producing novel immunoregulatory antibody-based cancer therapies which broaden our own pipeline and offer additional licensing and partnering opportunities" says BioInvent’s CEO Martin Welschof.

The Phase I/IIa study is one of four new clinical programs in solid cancers that the Company intends to initiate. These also include BI-1607 (an anti-FcγRllB antibody) in combination with a checkpoint inhibitor; BI-1808 (an anti-TNFR2 antibody); and the collaboration with Transgene to develop oncolytic viruses encoding a validated anti-CTLA-4 antibody.

About BioInvent